{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:51:29Z","timestamp":1785775889963,"version":"3.56.0"},"reference-count":22,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Curr. Issues Mol. Biol.","CIMB"],"abstract":"<jats:p>Cancer\/testis antigen (CTA) gene products are expressed in most malignant tumours, while under normal conditions their expression is primarily restricted to testicular cells. In this study, we investigated the prophylactic application of a xenogeneic (ram-derived) testicular cell (TC) vaccine for cancer prevention in an experimental animal model. C57BL\/6 mice were immunised three times with either xenogeneic (ram) or syngeneic (mouse) formaldehyde-fixed spermatogenic tissue-derived cells. Following vaccination, mice were implanted with live B16 melanoma or LLC carcinoma cells. Tumour-bearing mice were subsequently assessed for survival and immunological parameters indicative of anti-cancer immunity. Xenogeneic vaccination with TCs induced cross-reactive immune responses to both B16 melanoma and LLC carcinoma antigens (Ags), as determined by an MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Prophylactic vaccination with xenogeneic TCs (xTCs), but not syngeneic TCs (sTCs), significantly improved survival rates, with 30% of vaccinated mice surviving after LLC carcinoma implantation. The induced immunity was long-lasting as mice implanted with LLC carcinoma cells 3\u20136 months post-vaccination exhibited prolonged survival. Furthermore, lymphoid cells from surviving vaccinated mice were capable of adoptively transferring anti-cancer immunity to na\u00efve animals, significantly increasing their survival rates upon subsequent LLC carcinoma cell implantation. Vaccinated mice bearing LLC tumours exhibited a reduction in regulatory CD4\u207aCD25\u207aFoxp3\u207a T cells in the spleen, with no effect observed in the central memory CD4\u207aCD44\u207aCD62L\u207a T-cell compartment. Moreover, vaccinated mice displayed increased interferon gamma (IFN-\u03b3) levels in the blood, with no significant changes in interleukin-10 (IL-10) levels. Prophylactic vaccination with xenogeneic CTAs effectively induces long-term, stable anti-cancer immunity, demonstrating potential for future immunopreventive strategies.<\/jats:p>","DOI":"10.3390\/cimb47060443","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:53:16Z","timestamp":1749559996000},"page":"443","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Xenogeneic Testicular Cell Vaccination Induces Long-Term Anti-Cancer Immunity in Mice"],"prefix":"10.3390","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-8853","authenticated-orcid":false,"given":"Victor","family":"Seledtsov","sequence":"first","affiliation":[{"name":"Petrovsky National Research Centre of Surgery, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7109-4687","authenticated-orcid":false,"given":"Ayana","family":"Dorzhieva","sequence":"additional","affiliation":[{"name":"Institute for Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adas","family":"Darinskas","sequence":"additional","affiliation":[{"name":"Innovita Research Company, 06118 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-4761","authenticated-orcid":false,"given":"Alexei","family":"von Delwig","sequence":"additional","affiliation":[{"name":"Institute for Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Blinova","sequence":"additional","affiliation":[{"name":"Institute for Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Seledtsova","sequence":"additional","affiliation":[{"name":"Institute for Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14712598.2021.1828338","article-title":"Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer","volume":"21","author":"Seledtsov","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/testis antigens: Expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol. Invest."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gordeeva, O. (2018). Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy. Seminars in Cancer Biology, Academic Press.","DOI":"10.1016\/j.semcancer.2018.08.006"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: A knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ijo.2023.5519","article-title":"Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review)","volume":"62","author":"Ren","year":"2023","journal-title":"Int. J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biopha.2015.10.020","article-title":"Multiple-purpose immunotherapy for cancer","volume":"76","author":"Seledtsov","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/immu.200390005","article-title":"Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens","volume":"33","author":"Sioud","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"ref_9","first-page":"61","article-title":"Xenogenic cancer vaccines","volume":"32","author":"Potebnya","year":"2010","journal-title":"Exp. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/hum.2014.141","article-title":"Superior immunologic and therapeutic efficacy of a xenogeneic genetic cancer vaccine targeting carcinoembryonic human antigen","volume":"26","author":"Aurisicchio","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1016\/j.vaccine.2014.05.006","article-title":"Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: To use or not to use?","volume":"32","author":"Strioga","year":"2014","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.188.2.277","article-title":"gp100\/pmel 17 is a murine tumor rejection antigen: Induction of \u201cself\u201d-reactive, tumoricidal T cells using high-affinity, altered peptide ligand","volume":"188","author":"Overwijk","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1517\/14712598.2014.927433","article-title":"Xenogene vaccination in the therapy of cancer","volume":"14","author":"Cavallo","year":"2014","journal-title":"Expert Opin Biol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0167-5699(93)90261-I","article-title":"Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: A major obstacle for xenotransplantation in humans","volume":"14","author":"Galili","year":"1993","journal-title":"Immunol. Today."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00262-002-0286-2","article-title":"Immunotherapeutic potential of whole tumour cells","volume":"51","author":"Ward","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/08830185.2011.572210","article-title":"Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines","volume":"30","author":"Chiang","year":"2011","journal-title":"Int. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1084\/jem.191.3.423","article-title":"Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells","volume":"191","author":"Sauter","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1158\/0008-5472.CAN-04-1586","article-title":"Uric acid promotes tumor immune rejection","volume":"64","author":"Hu","year":"2004","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.celrep.2012.08.006","article-title":"Immune tolerance to tumor antigens occurs in a specialized environment of the spleen","volume":"2","author":"Ugel","year":"2012","journal-title":"Cell Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1172\/JCI89927","article-title":"Egress of sperm autoantigen from seminiferous tubules maintains systemic tolerance","volume":"127","author":"Tung","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Traynor, S., Jakobsen, M.K., Green, T.M., Komic, H., Palarasah, Y., Pedersen, C.B., Ditzel, H.J., Thoren, F.B., Guldberg, P., and Gjerstorff, M.F. (2024). Single-cell sequencing unveils extensive intratumoral heterogeneity of cancer\/testis antigen expression in melanoma and lung cancer. J. Immunother. Cancer., 12.","DOI":"10.1136\/jitc-2023-008759"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Seledtsov, V.I., Darinskas, A., Von Delwig, A., and Seledtsova, G.V. (2023). Inflammation control and immunotherapeutic strategies in comprehensive cancer treatment. Metabolites., 13.","DOI":"10.3390\/metabo13010123"}],"updated-by":[{"DOI":"10.3390\/cimb48080790","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000}}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/6\/443\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:24:44Z","timestamp":1785756284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/6\/443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["cimb47060443"],"URL":"https:\/\/doi.org\/10.3390\/cimb47060443","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}